Sequenom Enters Into License Agreement With Mayo Medical Laboratories

    Sequenom Enters Into License Agreement With Mayo Medical Laboratories

PR Newswire

SAN DIEGO, July 29, 2014

SAN DIEGO, July 29, 2014 /PRNewswire/ --Sequenom, Inc. (NASDAQ: SQNM), a life
sciences company that provides innovative genetic analysis solutions, and Mayo
Medical Laboratories (MML), the third-largest provider of esoteric laboratory
services in the United States, have announced a license agreement for
noninvasive prenatal testing patents and applications.

"We have great appreciation for Mayo Clinic's commitment to research,
innovation, and patient care, and we welcome the opportunity to partner with
the organization's leading clinical research laboratory to expand patient
access to this revolutionary technology," said William Welch, chief executive
officer of Sequenom, Inc.

Sequenom Laboratories first pioneered the use of noninvasive prenatal testing
in 2011 with the introduction of the MaterniT21^™ PLUS laboratory-developed
test that has helped more than 250,000 pregnant women worldwide who are at a
high risk for fetal chromosomal abnormalities. A December 2012 joint committee
opinion from the American Congress of Obstetricians and Gynecologists and the
Society of Maternal Fetal Medicine supports the use of cell-free fetal DNA
testing as an option for primary screening for pregnant women at increased
risk of aneuploidy (abnormal chromosomal number), including those 35 years of
age or older or who have a history of ultrasound abnormalities in pregnancy.

Terms of the agreement were not disclosed.

About Sequenom
Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to
improving health care through revolutionary genomic and genetic analysis
solutions. Sequenom develops innovative technologies, products, and diagnostic
tests that target and serve molecular diagnostic markets. Web site:

About Sequenom Laboratories
Sequenom Laboratories, a CAP-accredited and CLIA-certified molecular
diagnostics laboratory, has developed a broad range of laboratory tests, with
a focus on prenatal and ophthalmological diseases and conditions. Branded
under the names HerediT^™, MaterniT21^™ PLUS, RetnaGene^™, SensiGene^™ and
VisibiliT^™, these molecular genetic laboratory-developed tests provide early
patient-management information for obstetricians, geneticists, maternal fetal
medicine specialists, and ophthalmologists. Sequenom Laboratories is changing
the landscape in genetic-disorder diagnostics using proprietary cutting-edge

About Mayo Medical Laboratories and the Mayo Clinic Department of Laboratory
Medicine and Pathology
Mayo Medical Laboratories is the largest for-profit company associated with
Mayo Clinic, the world-renowned health care organization located in Rochester,
Minnesota. MML is the third-largest provider of esoteric laboratory services
in the United States and serves more than 5,000 clients in 130 countries. Mayo
Clinic's Department of Laboratory Medicine and Pathology maintains an active
diagnostic test-development program. These activities also incorporate
technologies from collaborations with diagnostic and biotechnology companies.
Mayo Clinic utilizes these proven diagnostic technologies in the care of its
patients and offers them to health care institutions through Mayo Medical
Laboratories. Revenue from this testing is used to support medical education
and research at Mayo Clinic.

Mayo Clinic is a nonprofit worldwide leader in medical care, research, and
education for people from all walks of life. For more information, visit or Journalists can become a member of the
Mayo Clinic News Network for the latest health, science, and research news and
access to video, audio, text, and graphic elements that can be downloaded or

SEQUENOM^®, HerediT^™, MaterniT21^™ PLUS, RetnaGene^™, SensiGene^™, and
VisibiliT^™ are trademarks of Sequenom, Inc. All other trademarks and service
marks are the property of their respective owners.

Forward-Looking Statement
Except for the historical information contained herein, the matters set forth
in this press release, including statements regarding Sequenom's expectations
related to future performance under the agreement between Sequenom and Mayo
Medical Laboratories, the expected or potential benefits and impact of the
agreement on Sequenom, patients and physicians, Sequenom's commitment to
improving health care through revolutionary genomic and genetic analysis
solutions, and Sequenom Laboratories' changing the landscape in genetic
disorder diagnostics, are forward-looking statements within the meaning of the
"safe harbor" provisions of the Private Securities Litigation Reform Act of
1995. These forward-looking statements are subject to risks and uncertainties
that may cause actual results to differ materially, including the risks and
uncertainties associated with market demand for and acceptance and use of
technology and tests such as the MaterniT21 PLUS test, reliance upon the
collaborative efforts of other parties and licensees such as Mayo Medical
Laboratories, healthcare providers and others, Sequenom or third parties
obtaining or maintaining regulatory approvals that impact Sequenom's business,
government regulation particularly with respect to diagnostic products and
laboratory developed tests, publication processes, the performance of designed
product enhancements, Sequenom's ability to develop and commercialize
technologies and products, particularly new technologies such as noninvasive
prenatal diagnostics and laboratory developed tests, Sequenom's financial
position, the timing and amount of reimbursement that Sequenom Laboratories
receives from payors for its laboratory developed tests, Sequenom's ability to
manage its existing cash resources or raise additional cash resources,
competition, intellectual property protection and intellectual property rights
of others, litigation involving Sequenom, and other risks detailed from time
to time in Sequenom's most recently filed reports on Form 8-K, its most
recently filed Quarterly Report on Form 10-Q and its Annual Report on Form
10-K for the year ended December 31, 2013, and other documents subsequently
filed with or furnished to the Securities and Exchange Commission. These
forward-looking statements are based on current information that may change
and you are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release. All
forward-looking statements are qualified in their entirety by this cautionary
statement, and Sequenom undertakes no obligation to revise or update any
forward-looking statement to reflect events or circumstances after the
issuance of this press release.



SOURCE Sequenom, Inc.

Contact: Sequenom Contacts: Carolyn Beaver, Chief Financial Officer, Sequenom,
Inc., 858-202-9028, or Rachel Kennedy, Media
Contact, Chandler Chicco Agency, 858-449-9575,
Press spacebar to pause and continue. Press esc to stop.